Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx(TM) PCR Platform to Support Submission to the U.S. FDA

Stock Information for Co-Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Co-Diagnostics Inc.

Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx(TM) Primer Ai(TM) Platform
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.